Melanoma: Diagnosis & Treatment at Memorial Sloan Kettering

Pictured: Jedd Wolchok We're finding new melanoma treatments. Medical oncologist Jedd Wolchok headed a clinical trial that led to FDA approval of the first drug to work against melanoma after it has metastasized.

At Memorial Sloan Kettering, our world-class experts in pathology, dermatology, medical oncology, surgery, and radiology focus exclusively on diagnosing and treating skin and eye melanoma. Approximately 1,200 people with melanoma come to us for care each year. We were integral in establishing standards of care for treating melanoma that have been adopted across the country and around the world.

Our team meets each week to discuss patients and treatment approaches. As a comprehensive cancer center, we are able to draw on the expertise of our MSK colleagues to treat melanoma that has spread (metastasized) to other parts of the body such as the lungs, bones, or brain.

Through our research, we have made enormous strides in treating melanoma, dramatically improving the chance for survival and a high quality of life for many people with the illness. Many of our patients choose to take part in clinical research that gives them access to tomorrow’s diagnostic and therapeutic techniques before they are widely available elsewhere.

In fact, all of the recently introduced melanoma drugs, such as ipilimumab (Yervoy™), were developed in studies conducted at MSK.